Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AMILI is a precision gut health company based in Singapore that operates Southeast Asia's first and largest microbiome bank. The company leverages its proprietary database of Asian microbiome profiles to develop personalized health solutions, including diagnostics, probiotics, and fecal microbiota transplants (FMT). AMILI's core technology, AMILI Prime, uses advanced analytics to provide insights into gut health and its links to various diseases. The company aims to address the lack of Asian representation in global microbiome research and provide tailored interventions for the region's population.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AMILI.